Lumen Health Tech Company Reveals New Data About Metabolism Training
7.1.2021 13:32:00 EET | Business Wire | Press release
Lumen, a health technology company at the forefront of metabolic health, has uncovered new data that reveals how training your metabolism is the greatest contributor to sustainable health and weight loss, not crash dieting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005400/en/
Lumen metabolism insights (Photo: Lumen)
The data analysis is based on 1 million metabolism measurements throughout 2020, as Lumen data scientists have discovered that metabolic flexibility, or the body's ability to efficiently switch between carbs and fats as an energy source, is the key to optimal health.
By focusing on optimising their metabolism, users were able to increase metabolic flexibility by 33%. Two-thirds also reported losing weight at a rate of 2 pounds per week on a consistent basis.
On the nutrition end, users successfully completed an average of 12 hour fasts and mostly followed their personalised nutrition plan according to what their metabolism measurement prescribed. The top 2% were able to start their day in a state of burning fat for 4 consecutive days. Naturally, users also became more active and completed an average of 1000 more steps a day, and slept at least 7 hours.
That's equivalent to walking to the supermarket, doing one weekly workout at home, eating a couple carb servings per meal with room for low-carb snacks, and eating dinner by 7pm followed by a decent night of sleep.
Research (Calcada et al, Gormsen et al) finds that people with good metabolic flexibility:
- Are in a better position to gain muscle and perform better during workouts
- Find it easier to lose weight and maintain it; and
- Are at lower risk of developing obesity, diabetes and metabolic disorders.
"Understanding how your body reacts to what you eat and how you exercise is crucial to training your metabolism. The base of performance, health and weight loss starts with your metabolism- and we are able to see the data of users worldwide improving their health every day just by being more aware of their body," said Barak Alon, head of data at Lumen.
In an effort to raise awareness for metabolic health and its many benefits, Lumen is launching a campaign entitled "New year, new metabolism" through a resource center with a downloadable health kit including extensive insights on nutrition and exercise to optimise metabolic health and flexibility.
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month.
Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Scientific Validation
Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.
Availability
The Lumen device is available at Lumen.me, currently priced at £299 with an MSRP of £349. The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.
Follow us on twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005400/en/
Contact information
Media contact: Kyla Blumenfeld, press@lumen.me
+972548161939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
